Lucira Health, Inc. (LHDX)
$0.3313
-0.01 (-2.50%)
Rating:
Recommendation:
-
| Symbol | LHDX |
|---|---|
| Price | $0.3313 |
| Beta | 0.000 |
| Volume Avg. | 5.64M |
| Market Cap | 13.450M |
| Shares () | - |
| 52 Week Range | 0.108-5.67 |
| 1y Target Est | - |
| DCF Unlevered | LHDX DCF -> | |
|---|---|---|
| DCF Levered | LHDX LDCF -> | |
| ROE | -89.63% | Strong Sell |
| ROA | -75.73% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 210.70% | Strong Buy |
| P/E | - | |
| P/B | 0.22 | Neutral |
Latest LHDX news
About
Download (Excel)Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.